184 related articles for article (PubMed ID: 34064291)
1. Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice.
Lo WL; Lo SW; Chen SJ; Chen MW; Huang YR; Chen LC; Chang CH; Li MH
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34064291
[TBL] [Abstract][Full Text] [Related]
2. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
3. Imaging and biodistribution of radiolabeled SP90 peptide in BT-483 tumor bearing mice.
Lo WL; Liang CH; Chen LC; Lee SY; Lo SN; Chen MW; Lu RM; Liu IJ; Wu HC; Chang CH
Appl Radiat Isot; 2020 Jul; 161():109162. PubMed ID: 32561130
[TBL] [Abstract][Full Text] [Related]
4. Radiosynthesis, Biological Evaluation, and Preclinical Study of a
Pirooznia N; Abdi K; Beiki D; Emami F; Arab SS; Sabzevari O; Pakdin-Parizi Z; Geramifar P
Contrast Media Mol Imaging; 2020; 2020():8421657. PubMed ID: 32292304
[TBL] [Abstract][Full Text] [Related]
5. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
6. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
7. Comparison of biological properties of (111)In-labeled dimeric cyclic RGD peptides.
Zheng Y; Ji S; Tomaselli E; Yang Y; Liu S
Nucl Med Biol; 2015 Feb; 42(2):137-45. PubMed ID: 25459111
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and comparative assessment of a labeled RGD peptide bearing two different ⁹⁹mTc-tricarbonyl chelators for potential use as targeted radiopharmaceutical.
Psimadas D; Fani M; Gourni E; Loudos G; Xanthopoulos S; Zikos C; Bouziotis P; Varvarigou AD
Bioorg Med Chem; 2012 Apr; 20(8):2549-57. PubMed ID: 22445386
[TBL] [Abstract][Full Text] [Related]
9. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
[TBL] [Abstract][Full Text] [Related]
10. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
11. Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591.
Tolmachev V; Varasteh Z; Honarvar H; Hosseinimehr SJ; Eriksson O; Jonasson P; Frejd FY; Abrahmsen L; Orlova A
J Nucl Med; 2014 Feb; 55(2):294-300. PubMed ID: 24408895
[TBL] [Abstract][Full Text] [Related]
12. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists.
Dijkgraaf I; Kruijtzer JA; Frielink C; Soede AC; Hilbers HW; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
Nucl Med Biol; 2006 Nov; 33(8):953-61. PubMed ID: 17127167
[TBL] [Abstract][Full Text] [Related]
14. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors.
Kumar SR; Deutscher SL
J Nucl Med; 2008 May; 49(5):796-803. PubMed ID: 18413389
[TBL] [Abstract][Full Text] [Related]
15. Dimeric DOTA-alpha-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity.
Bapst JP; Froidevaux S; Calame M; Tanner H; Eberle AN
J Recept Signal Transduct Res; 2007; 27(5-6):383-409. PubMed ID: 18097939
[TBL] [Abstract][Full Text] [Related]
16. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.
Chakraborty S; Shi J; Kim YS; Zhou Y; Jia B; Wang F; Liu S
Bioconjug Chem; 2010 May; 21(5):969-78. PubMed ID: 20387808
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys).
Alves S; Correia JD; Gano L; Rold TL; Prasanphanich A; Haubner R; Rupprich M; Alberto R; Decristoforo C; Santos I; Smith CJ
Bioconjug Chem; 2007; 18(2):530-7. PubMed ID: 17373771
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of ανβ3-mediated tumor expression with a 99mTc-labeled ornithine-modified RGD derivative during glioblastoma growth in vivo.
Tsiapa I; Loudos G; Fragogeorgi EA; Bouziotis P; Psimadas D; Xanthopoulos S; Paravatou-Petsotas M; Palamaris L; Varvarigou AD; Karnabatidis D; Kagadis GC
Cancer Biother Radiopharm; 2014 Dec; 29(10):444-50. PubMed ID: 25405951
[TBL] [Abstract][Full Text] [Related]
20. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
